CSNK2B and Spastic paraplegia: The deletion fully removes CSNK2B, LY6G5B and LY6G5C, and its breakpoints affect GPANK1 and ABHD16A. GPANK1, LY6G5B and LY6G5C currently have no disease association, and while ABHD16A is associated with autosomal recessive spastic paraplegia-86 (MIM#619735), there is no apparent second hit in ABHD16A, and the phenotype of the proband does not comprise spastic paraplegia.